Cellectis Reports Financial Results For First Quarter 2024 :

. Cellectis announced completion of the additional equity investment of $140M by AstraZeneca . Cash position of $143 million as of March 31

Related Keywords

France , United States , United Kingdom , Marc Dunoyer , Bing Wang , Nasdaq , International Accounting Standards Board , Cellectis The Company Euronext Growth , Allogeneic Car Development Programs , European Union , Research Plan , Astrazeneca , International Financial Reporting Standards , Euronext Growth , Chief Executive Officer , Development Programs , Investment Agreements , Arthur Stril , Interim Chief Financial Officer , Tyrell Rivers , Subsequent Investment Agreement , Net Income , Regarding Use , North Carolina ,